novel
human
coronaviru
hcov
year
recogn
etiolog
agent
sever
acut
respiratori
syndrom
two
hcov
known
year
recent
involv
nosocomi
respiratori
viral
infect
highrisk
children
howev
diagnosi
routin
perform
current
reliabl
immunofluoresc
cell
cultur
methodolog
avail
part
fouryear
epidemiolog
studi
pediatr
neonat
intens
care
unit
perform
demonstr
reliabl
revers
transcriptionpcrhybrid
assay
detect
hcov
antigen
group
clinic
respiratori
specimen
hospit
children
children
newborn
staff
member
found
high
incid
infect
revers
transcriptionpcrhybrid
assay
gave
high
specif
sensit
tissu
cultur
infect
dose
per
ml
techniqu
reliabl
applic
screen
larg
number
clinic
sampl
would
improv
diagnosi
hcov
respiratori
infect
knowledg
virus
epidemiolog
q
detect
human
coronaviru
nasal
specimen
larg
scale
studi
use
rtpcr
hybrid
assay
nosocomi
respiratori
viral
infect
nrvi
increasingli
document
pediatr
unit
respiratori
syncyti
viru
rsv
influenza
virus
rhinovirus
common
etiolog
viral
agent
novel
human
coronaviru
hcov
year
identifi
caus
agent
sever
acut
respiratori
syndrom
sar
cov
two
other
hcov
known
year
recent
recogn
import
caus
nrvi
highrisk
infant
report
previous
high
incid
hcov
among
nrvi
hospit
preterm
neonat
concomit
hcov
isol
staff
member
pediatr
neonat
intens
care
unit
hcov
envelop
virus
long
kb
singlestrand
infecti
rna
sinc
monoclon
antibodi
avail
routin
immunofluoresc
detect
clinic
strain
antigen
group
hcov
well
adapt
convent
cell
cultur
system
diagnosi
routin
perform
reliabl
diagnost
tool
need
studi
epidemiolog
hospit
care
unit
appropri
tool
hcov
diagnosi
sensit
suitabl
larg
scale
test
respiratori
specimen
feasibl
revers
transcriptionpcr
rtpcr
higher
sensit
compar
detect
hcov
previous
demonstr
sever
amplif
strategi
alreadi
report
studi
use
previous
describ
rtpcr
methodolog
follow
hybrid
detect
screen
directli
near
nasal
sampl
hospit
children
staff
member
without
previou
cell
passag
evalu
reliabl
techniqu
larg
prospect
studi
propag
inocul
suscept
cell
line
human
embryon
lung
strain
human
coronaviru
obtain
professor
talbot
quebec
canada
origin
came
american
type
cultur
collect
atcc
rockvil
md
usa
cell
grown
humidifi
atmospher
contain
vv
co
earl
minim
essenti
medium
hank
vv
eurobio
le
uli
franc
supplement
wv
sodium
bicarbon
mgml
gentamicin
panpharma
franc
ul
penicillin
eurobio
gl
streptomycin
eurobio
fetal
bovin
serum
vv
gibco
cergi
pontois
franc
fourth
passag
suscept
cell
line
yield
viral
suspens
titer
tissu
cultur
infect
dose
per
ml
tcid
ml
kept
use
rtpcr
experi
infecti
viru
titer
refer
strain
use
evalu
rtpcr
method
measur
indirect
test
monoclon
antibodi
mous
mab
obtain
professor
talbot
quebec
canada
describ
previous
check
specif
rtpcrenzym
immunoassay
eia
use
clinic
strain
rsv
influenza
type
b
parainfluenza
adenoviru
nasal
specimen
use
studi
clinic
specimen
prospect
survey
nrvi
pediatr
neonat
intens
care
unit
novemb
octob
march
decemb
nasal
specimen
collect
admiss
thereaft
weekli
basi
hospit
children
use
cytolog
brush
entir
experiment
protocol
collect
sampl
previous
describ
briefli
nasal
specimen
collect
month
staff
member
nurs
physician
involv
direct
patient
care
total
nasal
specimen
analyz
rtpcr
hybrid
method
communityacquir
infect
defin
posit
viral
detect
admiss
nosocomi
infect
neg
specimen
admiss
posit
viral
detect
h
later
one
aliquot
suspens
nasal
cell
collect
store
rna
extract
part
wash
phosphat
buffer
salin
pb
ph
centrifug
g
min
cell
resuspend
pb
distribut
slide
dri
fix
min
cold
aceton
slide
frozen
analysi
adenoviru
rsv
influenza
b
parainfluenza
describ
posit
neg
control
includ
treat
way
patient
sampl
total
rna
extract
ml
frozen
nasal
cell
dilut
pb
qiaamp
viral
rna
kit
qiagen
courtaboeuf
franc
accord
manufactur
protocol
rna
elut
ml
kit
elut
buffer
preserv
qualiti
rna
extract
limit
loss
viral
titer
store
rtpcr
perform
rtpcr
carri
micropl
perkin
elmer
appli
biosystem
courtaboeuf
franc
final
volum
ml
primer
pair
use
target
nucleocapsid
gene
respect
posit
revers
transcript
amplif
cdna
perform
tube
recommend
manufactur
access
rtpcr
system
promega
franc
briefli
ml
reaction
mix
contain
amvtfl
reaction
buffer
mm
dntp
mix
mm
primer
mm
mgso
u
avian
myeloblastosi
viru
revers
transcriptas
u
tfl
dna
polymeras
ml
rna
extract
rtpcr
perform
follow
perkin
elmer
thermocycl
pe
appli
biosystem
courtaboeuf
franc
min
min
threestep
cycl
denatur
min
anneal
min
extens
final
min
extens
step
product
store
rtpcr
carri
includ
mani
patient
rna
extract
neg
posit
control
rna
extract
dilut
known
titer
tcid
ml
pcr
amplif
product
detect
dna
enzym
immunoassay
genetik
deia
diasorin
antoni
franc
first
rtpcr
product
denatur
min
immedi
place
ice
hcov
singlestrand
dna
hybrid
biotinyl
probe
ggaagtgcaggtgttgtggc
target
nucleocapsid
gene
previous
coat
streptavidinco
well
microtit
plate
antidoubl
strand
dna
mous
monoclon
antibodi
use
detect
hybrid
present
specif
hybrid
reveal
enzym
tracer
protein
conjug
horseradish
peroxidas
determin
optim
probe
concentr
coat
ngml
test
carri
accord
manufactur
recommend
briefli
ml
rtpcr
product
ad
streptavidinco
micropl
well
ml
bind
buffer
one
hour
follow
three
wash
step
kit
wash
buffer
ml
antidoubl
strand
dna
dilut
ad
well
sampl
incub
room
temperatur
min
wash
ml
dilut
enzym
tracer
ad
micropl
incub
min
room
temperatur
wash
reaction
develop
addit
ml
substrat
absorb
read
nm
photomet
cutoff
valu
posit
express
optic
densiti
od
defin
mean
od
neg
control
plu
constant
valu
absorb
unit
given
kit
recommend
posit
sampl
show
od
valu
mean
neg
control
falseposit
result
link
contamin
prevent
perform
step
extract
amplif
hybrid
differ
area
laboratori
includ
neg
control
step
rtpcreia
protocol
clinic
sampl
test
indirect
detect
rsv
influenza
type
b
parainfluenza
type
adenoviru
first
ml
monoclon
antibodi
specif
viru
argen
varhil
franc
ad
well
left
min
wash
pb
airdri
follow
addit
fluoresceinlabel
antimous
immunoglobulin
incub
min
pb
wash
rins
water
mount
glycerol
slide
observ
immedi
fluoresc
microscop
store
determin
sensit
rtpcreia
perform
ml
success
logarithm
dilut
refer
strain
titer
tcid
ml
highest
dilut
yield
posit
signal
consid
detect
limit
assay
dilut
score
posit
rtpcr
hybrid
assay
dose
equival
approxim
ml
determin
titrat
viru
stock
microwel
cell
cultur
evalu
specif
hcov
primer
probe
clinic
strain
human
respiratori
virus
test
rtpcr
hybrid
assay
rsv
influenza
type
b
parainfluenza
adenoviru
amplif
occur
viru
strain
data
shown
cohort
total
children
elig
two
time
period
respect
n
n
total
specimen
analyz
children
staff
respect
viral
infect
diagnos
children
incid
posit
sampl
main
pathogen
observ
infect
children
eighti
communityacquir
infect
detect
children
incid
sixti
hcov
nine
rsv
seven
influenza
three
adenoviru
one
parainfluenza
type
involv
tabl
nine
sampl
posit
two
virus
four
hcov
rsv
three
hcov
influenza
two
influenza
adenoviru
gener
incid
nrvi
infant
hcov
five
parainfluenza
type
one
neonat
present
two
nosocomi
infect
tabl
communityacquir
nosocomi
infect
infant
staff
infect
period
studi
hcov
seventi
sampl
posit
staff
involv
hcov
one
influenza
first
period
novemb
octob
high
incid
hcov
posit
sampl
children
specimen
staff
member
specimen
sixtythre
communityacquir
infect
found
hcov
hcovrel
nosocomi
infect
incid
mostli
tabl
second
epidem
period
march
decemb
lower
incid
hcov
posit
sampl
first
period
children
specimen
staff
member
moreov
incid
hcovrel
nosocomi
infect
low
infect
children
incid
tabl
diagnost
laboratori
routin
screen
coronaviru
infect
epidemiolog
studi
conduct
mainli
use
serolog
assay
detect
coronaviru
infect
howev
techniqu
suitabl
diagnost
respiratori
infect
poor
sensit
requir
two
success
blood
sampl
cell
cultur
prove
unreli
primari
isol
human
respiratori
coronavirus
inde
hcov
strain
grow
cell
cultur
adapt
diagnosi
respiratori
viral
infect
mainli
base
diagnosi
hcov
infect
one
specif
monoclon
antibodi
argen
varilh
franc
avail
longer
commerci
one
us
pj
talbot
inrsinstitut
armandfrappi
research
center
develop
two
monoclon
antibodi
direct
protein
diagnosi
procedur
assay
use
antibodi
appear
less
sensit
rtpcrdeia
describ
current
studi
test
cours
larg
scale
epidemiolog
studi
use
rtpcr
hybrid
method
rapid
specif
sensit
detect
dna
product
hybrid
specif
sensit
agaros
gel
visual
micropl
enzym
immunoassay
format
allow
handl
larg
number
sampl
need
epidemiolog
studi
anoth
advantag
rtpcr
methodolog
detect
viru
genom
present
low
titer
viru
replic
compet
valu
rtpcr
techniqu
certain
import
respiratori
virus
name
human
rhino
coronavirus
clear
practic
rapid
techniqu
avail
sever
recent
studi
use
molecular
techniqu
rtpcr
follow
hybrid
step
viral
diagnosi
adapt
valid
methodolog
larg
scale
epidemiolog
studi
requir
process
numer
sampl
minim
time
labor
associ
origin
molecular
hcovspecif
detect
protocol
time
need
diagnosi
rtpcrdeia
methodolog
carri
micropl
enabl
rapid
multichannel
pipet
shorter
requir
cell
cultur
associ
detect
day
longer
perform
directli
nasal
aspir
howev
techniqu
sensit
rtpcr
eightyf
clinic
sampl
test
parallel
within
h
rtpcrdeia
describ
current
studi
make
reliabl
screen
techniqu
suitabl
epidemiolog
studi
detect
rtpcrdeia
sensit
ml
limit
detect
compar
well
valu
previous
obtain
other
ml
respect
moreov
threshold
repres
accept
titer
detect
virus
implic
clinic
event
vabret
et
al
use
system
target
gene
membran
protein
abund
hcov
protein
howev
rna
encod
n
abund
encod
protein
infect
cell
thu
chosen
reliabl
target
rtpcr
perform
survey
nrvi
period
modul
interannu
variat
epidemiolog
viral
infect
coronavirusrel
nrvi
mirror
commun
infect
epidem
everi
year
studi
shorter
time
frame
may
underestim
hcov
infect
widespread
respons
onethird
common
cold
children
adult
detect
nasal
swab
sampl
patient
acut
flulik
ill
also
human
brain
autopsi
sampl
suggest
may
also
involv
etiolog
sever
diseas
age
group
pneumonia
perimyocard
etc
abil
coronavirus
caus
sever
diseas
anim
rais
possibl
coronaviru
could
also
caus
sever
diseas
human
sarsrel
coronaviru
appear
exampl
coronaviru
associ
sever
diseas
human
pediatr
unit
pathogen
role
hcov
remain
undefin
techniqu
reagent
avail
diagnosi
role
lower
respiratori
infect
unclear
howev
suspect
involv
exacerb
asthma
children
hcov
also
isol
digest
tract
role
gastrointestin
diseas
unproven
neonat
screen
program
hcov
place
neonat
pediatr
unit
brest
year
first
studi
retrospect
one
respiratori
specimen
found
posit
newborn
result
confirm
prospect
studi
show
hcov
incid
symptomat
neonat
gestat
age
week
prospect
observ
studi
carri
determin
role
hcov
nosocomi
infect
pediatr
icu
preliminari
result
show
incid
first
winter
hcov
nosocomi
transmiss
via
medic
staff
suspect
transmiss
virus
possibl
via
air
hand
contamin
moreov
year
hcovrel
outbreak
identifi
correl
concomit
high
preval
hcov
staff
member
prospect
studi
hcov
identifi
main
pathogen
caus
nrvi
infant
newborn
conclus
littl
known
hcov
epidemiolog
appropri
diagnost
method
avail
studi
demonstr
reliabl
rtpcr
associ
detect
hybrid
analysi
larg
number
clinic
specimen
techniqu
would
facilit
costeffect
diagnosi
improv
clinic
manag
respiratori
tract
symptom
hospit
infect
children
therebi
limit
unnecessari
antibiot
use
techniqu
invalu
epidemiolog
studi
need
firmli
establish
medic
import
human
coronavirus
